³í¹®) Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in nonalcoholic fatty liver disease ¼¿ï´ëº´¿ø¿î¿µ ¼¿ïƯº°½Ã º¸¶ó¸Åº´¿ø(¿øÀå ±èº´°ü) ¼Òȱ⳻°ú ±è¿ø ±³¼ö(»çÁø)